Tazobactum%2525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a combination penicillin-class antibacterial and a beta-lactamase inhibitor. It has broad-spectrum activity against many Gram-positive, Gram-negative, and anaerobic bacteria. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections * Community-acquired pneumonia * Nosocomial pneumonia (hospital-acquired pneumonia) ## Adult Dosing The typical dose is 3.375 g (3 g piperacillin/0.375 g tazobactam) or 4.5 g (4 g piperacillin/0.5 g tazobactam) administered intravenously every 6 or 8 hours. Dosing frequency and duration depend on the type and severity of infection, and patient response. For severe infections, higher doses may be used. Consult institutional guidelines for specific indications and durations. ## Pediatric Dosing For patients 2 months of age and older: * **Complicated intra-abdominal infections:** Dosing is typically based on piperacillin weight-based dose of 100 mg/kg every 8 hours (for 3.375 g formulation) or every 6 hours (for 4.5 g formulation). Maximum dose is 4 g per dose (piperacillin component) every 6 or 8 hours. * **Complicated skin and skin structure infections:** Dosing is typically based on piperacillin weight-based dose of 75 mg/kg every 8 hours (for 3.375 g formulation) or every 6 hours (for 4.5 g formulation). Maximum dose is 4 g per dose (piperacillin component) every 6 or 8 hours. Neonates and infants younger than 2 months: Use is generally not recommended due to immature renal function. ## Dose Adjustments * **Renal Impairment:** * CrCl > 20 mL/min: No dose adjustment needed. * CrCl ≤ 20 mL/min: Administer usual dose every 12 hours. * For intermittent hemodialysis: Administer usual dose every 12 hours, and administer an additional dose after each dialysis session. ## Contraindications * Known severe hypersensitivity to piperacillin, tazobactam, other penicillin antibiotics, or beta-lactamase inhibitors. * History of biliary dysfunction associated with piperacillin/tazobactam use. ## Adverse Effects Common adverse effects include diarrhea, nausea, vomiting, rash, headache, insomnia, and injection site reactions. Serious adverse effects include *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures, and interstitial nephritis. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin/tazobactam plasma concentrations. * **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade. * **Methotrexate:** Piperacillin may decrease methotrexate levels. * **Oral anticoagulants (e.g., warfarin):** May increase INR. Monitor INR closely. ## Monitoring * Monitor for signs and symptoms of hypersensitivity reactions. * Monitor for *Clostridioides difficile*-associated diarrhea. * Monitor renal function, especially in patients with pre-existing renal impairment or those receiving concomitant nephrotoxic agents. * Monitor for signs of bleeding or bruising in patients receiving oral anticoagulants. * Monitor liver function tests periodically. ## Clinical Pearls * Piperacillin/tazobactam is administered via intravenous infusion. Infusion times vary by product and dose. * Consider the spectrum of activity when choosing piperacillin/tazobactam. It may not cover all resistant organisms. * Culture and sensitivity testing should be performed before initiating therapy to guide treatment. * Reconstituted solutions have limited stability. Follow manufacturer recommendations for storage and administration. *** **Disclaimer:** This information is intended for clinical pharmacy use and does not replace the need for independent judgment or consultation of the official prescribing information. Always verify current dosing, indications, contraindications, warnings, precautions, and adverse reactions with the most up-to-date product literature and institutional guidelines.